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Abstract: Nanotechnology employs multifunctional engineered materials in the nanoscale range
that provides many opportunities for translational stem cell research and therapy. Here,
we present a cell penetrating peptide (virus-1 trans-activator of transcription, TAT) -
conjugated, porous silicon nanoparticle (TPSi NP) loaded with Wnt3a protein to
increase both the cell survival rate and the delivery precision of stem cell
transplantation via a combinational theranostic strategy. The TPSi NP with a pore size
of 10.7 nm and inorganic framework enabled high-efficiency loading of Wnt3a,
prolonged Wnt3a release and reduced antioxidative stress activity in the labeled
mesenchymal stem cells (MSCs), which are highly beneficial properties for cell
protection in stem cell therapy for myocardial infarction. We confirmed that the
intracellular aggregation of TPSi NPs can highly amplify the acoustic scattering of the
labeled MSCs, resulting in a 2.3-fold increase in the ultrasound (US) signal compared
with that of unlabeled MSCs. The translational potential of the designed nanoagent for
real-time US imaging-guided stem cell transplantation was confirmed via
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
intramyocardial injection of labeled MSCs in a nude mouse model. We propose that
the intracellular aggregation of protein drug-loaded TPSi NPs could be a simple but
robust strategy for improving the therapeutic effect of stem cell therapy.
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Nanotechnology employs multifunctional engineered materials in the nanoscale range 
that provides many opportunities for translational stem cell research and therapy. Here, 
we present a cell penetrating peptide (virus-1 trans-activator of transcription, TAT) 
-conjugated, porous silicon nanoparticle (TPSi NP) loaded with Wnt3a protein to 
increase both the cell survival rate and the delivery precision of stem cell 
transplantation via a combinational theranostic strategy. The TPSi NP with a pore size 
of 10.7 nm and inorganic framework enabled high-efficiency loading of Wnt3a, 
prolonged Wnt3a release and reduced antioxidative stress activity in the labeled 
mesenchymal stem cells (MSCs), which are highly beneficial properties for cell 
protection in stem cell therapy for myocardial infarction. We confirmed that the 
intracellular aggregation of TPSi NPs can highly amplify the acoustic scattering of the 
labeled MSCs, resulting in a 2.3-fold increase in the ultrasound (US) signal compared 
with that of unlabeled MSCs. The translational potential of the designed nanoagent 
for real-time US imaging-guided stem cell transplantation was confirmed via 
intramyocardial injection of labeled MSCs in a nude mouse model. We propose that 
the intracellular aggregation of protein drug-loaded TPSi NPs could be a simple but 





































































The technique of stem cell therapy holds great potential for treating a wide range of 
diseases, including cancer, skin and cardiovascular disease.[1] In particular, stem 
cell-based transplantation has become a promising therapeutic strategy for the 
regeneration of injured heart, owing to its ability to stimulate cardiac regeneration 
potential and reconstitute the cardiomyocyte loss.[1f] For therapeutic purposes, stem 
cells must be precisely delivered to the site of action and be able to sustainably secrete 
active factors or differentiate into specific cell lines in a relatively short period of time; 
however, both of these features are still unsatisfactory at the current stage and limit 
the progress of stem cell therapies.[2] 
To improve the therapeutic accuracy and efficiency of cardiac regeneration, 
multiple imaging techniques, such as magnetic resonance imaging, photoacoustic 
imaging and bioluminescence imaging, have been used as promising methods for 
stem cell labeling to guide cell delivery and to determine the survival and local 
activity of stem cells in implanted site.[3] Among different imaging techniques, 
ultrasound (US) imaging is more feasible for future clinical applications, because it is 
noninvasive, cost-effective, widely available, portable and allows molecular imaging 
and real-time guided imaging without any ionizing radiation effect.[4] One major 
approach is to label stem cells with US contrast agents to achieve enhanced imaging 
of cells.[5] Although different types of gas-filled microbubbles can be used as contrast 




































































structural stability (lifetime of 5-12 min) and micrometer-scale particle size limit their 
applications in cell labeling and monitoring.[6] 
To employ US-enhanced imaging with high stability and sensitivity, much effort 
has been focused on the design and fabrication of rigid inorganic nanoparticles (NPs) 
with relatively high structural stability and echogenic properties.[7] Recently, silica 
NP-based US contrast agents have received intensive interest, because of their low 
toxicity, adjustable structure and particle size, and their high performance in acoustic 
scattering at high US frequencies.[8] For example, Zhang et al. systematically 
investigated the effect of silica NP structure on the acoustic properties and showed 
that rattle-shaped mesoporous silica NPs exhibit superior US imaging capability 
compared with solid- and hollow-structured NPs.[9] Additionally, Jokerst et al. 
confirmed the feasibility of US imaging-guided delivery of stem cells into the 
myocardium with the use of a silica NP-based labeling agent.[10] However, the 
biodegradability and metabolism of silica NPs in biological body is still controversial, 
limiting their future clinical application.[11]  
  In addition, mesenchymal stem cells (MSCs), which are generally extracted from 
animal or human sources, have been widely investigated in basic and preclinical 
research for treating different injuries and diseases.[12] Although the safety of MSCs 
therapies has been consistently reported, their efficacy remains more elusive. In 
particular, their low survival rate in infarcted tissue (such as myocardium, liver and 




































































oxygen species (ROS) generated at the ischemic site of injury could dramatically 
induce the loss of transplanted MSCs.[14] Thus, a powerful strategy that can 
manipulate MSCs to significantly attenuate ROS-induced damage and thereby 
promote MSC survival and differentiation is urgently needed for both preclinical 
research and future clinical application of stem cell therapy.  
As a promising alternative, we propose replacing silica-based NPs with porous 
silicon nanoparticles (PSi NPs) to act as US contrast agents for cellular labeling and 
US imaging-guided stem cell transplantation (shown in Scheme 1). PSi materials have 
received wide attention in the field of biomedical nanotechnology, because these NPs 
are more biodegradable than silica NPs.[15] The porous structure of PSi NP is 
produced by electrochemical etching, which enables the tailored manipulation of pore 
size and pore volume for a high drug-loading capacity.[16] Therefore, we investigated 
the possibility of surface modification of PSi NPs with virus-1 trans-activator of 
transcription (TAT) peptide[17] to create a dual-functional enhanced imaging/protein 
drug delivery system with great potential for clinical translation (the obtained 
nanoparticle is denoted as TPSi NP). The possible cytotoxicity, in vivo safety and 
biodegradability of TPSi NP were systemically studied in this study. In addition, a 
typical multifunctional protein, Wnt3a, was used to evaluate the loading efficiency 
and release behavior of protein drug-loaded TPSi NP. Importantly, previous reports 
have confirmed the protective effect of Wnt3a against oxidative stress in cells through 
the Wnt/β-catenin signaling pathway.[18] However, since this protein drug generally 




































































stem cell therapy. Therefore, another important purpose of this study is to investigate 
the effect of Wnt3a-loaded TPSi NP on the cell protective activity for the labeled stem 
cells. This integrated technique presents concurrent US contrast imaging and protein 
drug delivery within one TPSi NP, which could offer remarkable advantages for future 
cardiac stem cell therapy. 
2. Results and Discussion 











Scheme 1. Schematic illustration of stem cells labeled with Wnt3a protein-loaded 
TPSi NPs injected intramyocardially into nude mice under US imaging guidance. 
 
The PSi NPs were constructed to have fluorescence and enhanced internalization 




































































thermal carbonization and surface modification with aminosilanes was conducted to 
obtain PSi NPs containing amine groups. Furthermore, the particle surface was 
chemically decorated with FITC-conjugated TAT peptide (TAT-FITC) by an 
esterification reaction to promote the cellular internalization of the NPs.[19] The TPSi 
NPs exhibit a porous structure as observed in transmission electron microscopy (TEM) 
images (Figure 1A, B). The profile from electron energy loss spectroscopy (EELS) 
mapping of particles in a TEM system confirmed that the main component of the 
particle product is Si (Figure 1B). Additionally, scanning electron microscopy (SEM) 
analysis of the obtained NPs showed a pore structure with an average pore size of ca. 
10.7 nm, as measured by ImageJ software (Figure 1C, Figure S1). Meanwhile, the N2 
sorption profile shows the particle exhibit specific surface area of 352 m2 g-1 and a 
total pore volume of 0.76 cm3 g-1 (Figure 1D). In addition, the successful conjugation 
of TAT-FITC peptide onto the surface of the TPSi NPs was confirmed by 
ultraviolet-visible (UV-Vis) spectroscopy. As indicated in Figure 1E, a significant 
decrease in the characteristic absorbance peak of TAT-FITC in solution was found 
after centrifugation of the NPs. Thus, it was calculated that ca. 71 mmol of peptide 
was conjugated per gram of TPSi NPs. We also found that the conjugation of 
TAT-FITC on TPSi NPs was quite stable, as no obvious optical absorption at 495 nm 
(the characteristic absorption of the released TAT-FITC) was observed for TAT-FITC 
conjugated TPSi NPs after immersion in ethanol for 24 h (Figure S2). Furthermore, as 
dynamic light scattering (DLS) result shown (Figure 1F), the TAT-conjugation can 




































































(PBS), owing to the chemical property change of particle surface. The hydrodynamic 












Figure 1. (A, B) TEM images of TPSi NPs at different magnifications. Inset image in 
Figure1B: EELS mapping of the element Si in TPSi NPs. (C) SEM image of TPSi 
NPs. (D) N2 adsorption–desorption isotherm for TPSi NPs. (E) UV-Vis absorption 
spectra of the initial TAT-FITC solution (black line) and the supernatant containing 
unbound TAT-FITC after sequential chemical conjugation of TAT-FITC and 
centrifugation of NPs (red line). (F) Hydrodynamic size distribution curves of PSi NP 
and TPSi NP in PBS.  
 
2.2. Cellular labeling 
After coincubation of MSCs with functionalized TPSi NPs at a concentration of 40 
μg mL-1 for 4 h, the cells were washed to remove the unbound TPSi NPs. Using 




































































(CLSM, Figure S3), we observed that a considerable amount of TPSi NPs localized to 
the MSCs. TEM imaging of the labeled MSCs revealed that the TPSi NPs were 
mainly localized in the cytoplasm and formed clusters with sizes ranging from 1-2 μm 
(Figure 2D-E, Figure S4). Additionally, energy-dispersive X-ray spectroscopy (EDS) 
spectra indicated the existence of the element Si within MSCs. Furthermore, the Si 
content inside the cells after MSC labeling was measured by inductively coupled 
plasma-atomic emission spectroscopy (ICP-AES), and the result showed that 
approximately 78.8 % of TPSi NPs were localized in the cell (Figure S5). However, 
only 52.7 % of TAT-unconjugated PSi NPs was internalized by MSCs under the same 
condition (Figure S5). The result reveals a high labeling efficiency of PSi NP resulting 









Figure 2. Fluorescence microscopy images of TPSi NP-labeled MSCs. (A) TPSi NPs 
with green fluorescence, (B) merged image of DAPI-stained nuclei and 
TRITC-phalloidin-stained f-actin, and (C) merged image of TPSi NPs, nuclei and 
f-actin. (D, E) TEM image of TPSi NPs within MSCs. (F) EDS spectra of the 





































































2.3. TPSi NP biodegradation 
The biodegradation behavior and the structural evolution of TPSi NPs in MSCs 
were further studied. MSCs were harvested and fixed in ultrathin sections for TEM 
observation after incubation with TPSi NPs to label the MSCs (TPSi NP concentration 
of 40 μg mL-1) for different periods (1, 8 and 16 days). As shown in Figure 3A, the 
particle diameter above 100 nm and the obvious porous structure were still present 
after 1 day. However, the extended coincubation for 8 days resulted in a dramatic 
decrease in particle size and a less organized pore structure for the TPSi NPs, 
indicating that significant biodegradation of TPSi NPs occurred in the MSCs. 
Furthermore, distinct changes in particle morphology and only several spherical 
objects with particle sizes below 10 nm were observed after incubation for 16 days. 
Collectively, the above results confirmed the feasibility of intracellular TPSi NP 
degradation. 
To further understand the mechanism by which the cellular environment influences 
the biodegradation of TPSi NPs, the TPSi NPs were placed in PBS at three 
representative pH values (5.4, 7.4 and 8.4) to investigate the corresponding Si ion 
release rate. The free Si ions were quantitatively measured after different durations 
(1-16 days) by ICP-AES. As shown in Figure 3B, gradual silicate ion leaching of 
TPSi NPs into the solution was observed when placed in pH 7.4 PBS, and the 




































































debris-like silicon fragments were observed in the TEM image (Figure 3C). In 
contrast, the silicate ion release increased significantly at pH 8.4, with ca. 84% of 
silicate ions leaching into solution in 16 days (Figure 3B), which indicates that the 
basic environment has a positive effect on the biodegradation of TPSi NPs. In contrast 
to the TPSi NPs in both neutral and alkaline conditions, the TPSi NPs maintained 
their large pore structure in the weakly acidic solution (pH 5.4) as shown in Figure 3D 
and S6, and only approximately 5% of silicate ion was released within 16 days. The 
above results confirmed the hydroxide ions existed in stem cells may be the main 









Figure 3. (A) TEM images of randomly selected MSCs containing TPSi NPs after 
coincubation for 1, 8 and 16 days. The right panel shows the magnified image of a 
representative region (as indicated by the white arrow) in the left panel. (B) Silicate 
release percentages of TPSi NPs after being immersed in PBS with different pH 
values (5.4, 7.4 and 8.4) for different time periods. (C, D) TEM images of TPSi NPs 





































































2.4. Effect of TPSi NP labeling on MSC survival and differentiation 
The cytotoxicity of TPSi NPs at different concentrations (0, 6.25, 12.5, 25, 50, 100, 
200 μg mL-1) against MSCs was first evaluated to confirm the feasibility of TPSi NPs 
for biological applications. After MSCs were cocultured with different concentrations 
of TPSi NPs for 48 h, cell viability was determined by both the cell counting Kit-8 
(CCK-8) and the lactate dehydrogenase (LDH) assays (Figure 4A, B). The results 
suggest that the TPSi NPs had no adverse effect on the survival of MSCs. 
MSCs possess the capability to differentiate into multiple cell types, including 
adipocytes, osteoblasts and chondrocytes.[21] When TPSi NPs are applied for 
intracellular labeling of MSCs, it is necessary to evaluate their potential adverse 
effects on the differentiation capability of MSCs. First, the effects of TPSi NPs at 
different concentrations (0, 40, 60 and 80 μg mL-1) on the induction of MSCs to 
myocyte-like cells were evaluated. The bone morphogenetic protein-2 (BMP-2) and 
fibroblast growth factor-4 (FGF-4) were used to stimulate the MSCs differentiation.[22] 
After treatment for two weeks, stretching pseudopodia and cell cluster formation were 
observed for each cell sample with and without pretreatment by TPSi NPs. The 
expression of GATA-4 and cardiac troponin I (cTnI) in each group was measured, 
which serve as specific markers of cardiomyocyte-like cells.[22a] As shown in Figure 
4C and Figure S7, no significant difference in the GATA-4 expression was observed 
in each induction group no matter pretreated with TPSi NPs (1.06±0.16, 1.17±0.17 




































































(1.03±0.19). In addition, their cTnI expression, as reflected by green fluorescence, 
was visually detected by confocal laser scanning microscopy (CLSM), as indicated in 
Figure 4D. The mean fluorescence level measured by flow cytometry was 45.82±2.15, 
42.14±1.64 and 38.56±1.32 for MSCs without and with pretreatment with TPSi NPs 
(40 and 60 μg mL-1), respectively, which differed from each other nonsignificantly 
(P>0.05). In comparison, the fluorescence level decreased slightly to 28.84±1.15 
when the TPSi NP concentration was 80 μg mL-1. In addition, the proportion of 
cTnI-positive cells was lower when pretreated with such high TPSi NP concentration 
(80 μg mL-1) than that without TPSi NP pretreatment (68.45±3.65% vs. 88.88±1.21%, 
P<0.05, Figure 4E). These results indicate that the TPSi NPs at the concentration 
above 80 μg mL-1 may induce adverse effect to the cardiomyogenic differentiation of 
MSCs. Overall, our result demonstrated that TPSi NPs at concentrations lower than 
60 μg mL-1 exert a negligible effect on the induction of cardiomyocyte-like cells by 
BMP-2 and FGF-4. 
Furthermore, three other typical in vitro differentiation assays (adipogenic, 
osteogenic and chondrogenic) of MSCs were conducted with and without 
pretreatment with TPSi NPs (particle concentration: 100 μg mL-1). The adipogenic 
differentiation assay showed that intracellular lipid vesicles formed for both TPSi 
NP-treated MSCs and untreated MSCs after adipogenic induction (Figure S8A). 
Additionally, the quantification of the Oil red O-stained cells shows no obvious 
change in the labeled MSCs compared with the unlabeled MSCs (Figure S8B). We 




































































in Figure S9A, calcium deposits were observed in TPSi NP-labeled cells after 14 days 
of differentiation induction. Additionally, quantitative analysis via Alizarin Red 
staining showed similar levels of osteogenic differentiation between MSCs with and 
without TPSi NP labeling (Figure S9B). Similarly, for the evaluation of chondrogenic 
differentiation, the trend for MSCs to differentiate into chondrocytes was not 
obviously affected by TPSi NP labeling (Figure S10A). No obvious quantitative 
differences in the proportion of alcian blue-stained area were found between TPSi 
NP-labeled MSCs and unlabeled MSCs (Figure S10B). Therefore, these data prove 
that TPSi NP labeling at concentrations less than 60 μg mL-1 exhibits feasible 











Figure 4. (A, B) Effect of TPSi NP labeling on the cell survival of MSCs determined 
by the (A) CCK-8 and (B) LDH assays. (C-E) Effect of TPSi NP labeling on the 
cardiomyocyte differentiation of MSCs. (C) Quantification data of GATA-4 proteins 
in MSCs after induction with BMP-2 and FGF-4 in the presence of TPSi NPs at 




































































80 μg mL-1, IV: 0 μg mL-1). V indicates the control group without induction. 
*Significant difference compared with the control group by one-way ANOVA analysis 
(P<0.05) (D) CLSM images showing the cTnI expression (green fluorescence) levels 
in MSCs without induction (left) and after BMP-2/FGF-4 induction in the absence 
(middle) and presence of 40 μg mL-1 TPSi NPs (right). (E) Percentage of cTnI 
positive cells in MSCs after BMP-2/FGF-4 induction in the presence of different 
concentrations of TPSi NPs determined by flow cytometry analysis. 
 
2.5. Wnt3a protein loading and sustained release of Wnt3a@TPSi NPs 
The involvement of Wnt/β-catenin signaling in numerous biological processes, 
including cell proliferation, antioxidative stress and cardiac differentiation of MSCs, 
has been intensively investigated in recent years.[23] In particular, exogenous Wnt3a 
protein can attenuate β-catenin degradation and promote its nuclear localization by 
increasing the level of glycogen synthase kinase-3β (GSK-3β) phosphorylation. 
Therefore, it has been recognized as a potential protein drug for activating 
Wnt/β-catenin signaling. Unfortunately, the application of Wnt3a protein for stem cell 
protection is limited by its poor structural stability and dramatic aggregation in 
serum-free media.[24] Hence, an efficient strategy to enhance the bioavailability of 
Wnt3a protein is necessary to protect MSCs against oxidative damage. Silicon 
nanomaterial with suitable pore size is generally considered an efficient protective 
carrier for active proteins.[25] The loading process and sustained release behavior of 
Wnt3a protein in TPSi NPs are shown in Figure 5A. Wnt3a protein could be easily 
adsorbed in the porous framework of TPSi NPs, and the quantification result based on 




































































loading efficiency was calculated to be ca. 98.1%) was successfully loaded in TPSi 
NPs by simple mixing the protein and NPs at 4°C for 1 h (Figure S11). This high 
loading efficiency could be ascribed to suitable pore size, the large surface area of 
TPSi NPs and their strong electrostatic interactions with the negatively charged 
Wnt3a protein. These features are favorable not only for protein loading, but also for 
hindering its rapid release.[26] For release evaluation, a pellet of Wnt3a-loaded TPSi 
NPs was immersed in PBS with gentle shaking to mimic the normal physiological 
environment. As we anticipated, Figure 5B shows sustained release of Wnt3a that 











Figure 5. (A) Schematic illustrations of the Wnt3a loading process and sustained 
release from TPSi NPs. (B) The release curve of Wnt3a from TPSi NPs. (C-G) 
Western blot bands and protein levels of p-GSK-3β (C, E), total GSK-3β (C, D) and 
β-catenin (F, G) in H2O2-stimulated MSCs (denoted H2O2), free Wnt3a (CWnt3a=150 
ng mL-1)-treated/H2O2-stimulated MSCs (denoted F150+H2O2), and Wnt3a@TPSi NPs 
(CWnt3a=150 ng mL
-1)-labeled/H2O2-stimulated MSCs (denoted Si150+H2O2). The 
concentration of TPSi NP in group Si150+H2O2 is about 6.1 µg mL




































































and ** P<0.01 by the t-test. 
 
2.6. Antioxidative stress effect and mechanism of Wnt3a@TPSi NPs 
The sustained release of Wnt3a proteins from TPSi NP is considered favorable for 
prolonging their activity in the absence of serum. To confirm this effect, we 
comparatively evaluated the abilities of Wnt3a in a free formulation and loaded in 
TPSi NPs to protect MSCs against oxidative stress in serum-free culture conditions. 
The MSCs were exposed to serum-free cell medium containing different 
concentrations of H2O2 in the range of 50-400 μM for 24 h, and the cell viability was 
then measured via the CCK-8 assay to determine the effect of H2O2 concentration on 
the cell survival rate. Figure S12 indicates that the extent of oxidative damage induced 
by H2O2 increased significantly in a concentration-dependent manner. The H2O2 
concentration of 100 μM, which induces moderate cell damage, was chosen for this 
study to simulate the oxidative stress condition after myocardial damage. 
The ability of free Wnt3a and Wnt3a-loaded TPSi NPs to influence canonical Wnt 
signaling under conditions with H2O2 treatment was examined by quantifying changes 
in GSK-3β phosphorylation and nuclear β-catenin levels in MSCs (Figure 5C-G).[27] 
Western blot analysis revealed clear decreases in GSK-3β phosphorylation and 
nuclear β-catenin levels in MSCs upon H2O2 stimulation (Figure 5C, D). However, it 
was found that pretreatment of free Wnt3a or Wnt3a-loaded TPSi NPs with MSCs 




































































importantly, the GSK-3β in the MSCs labeled with Wnt3a-loaded TPSi NPs displayed 
a higher extent of phosphorylation than free Wnt3a. Additionally, increased nuclear 
localization of β-catenin was also observed in both Wnt3a-containing groups (Figure 
5F, G). Notably, the levels of β-catenin in the nuclear compartment was ca. 45% 
higher for the Wnt3a-loaded TPSi NP group than the free Wnt3a group (Figure 5G). 
These results suggest the superior performance of Wnt3a-loaded TPSi NPs in 
promoting Wnt/β-catenin-dependent signaling. 
Furthermore, quantification of the protein expression of both Bax and Bcl-2 in free 
Wnt3a- and Wnt3a@TPSi NP-treated MSCs after stimulation with H2O2 (100 μM) for 
24 h was carried out via western blotting (Figure 6A, B). The ratio of Bax/Bcl-2 
reflects the cell sensitivity to H2O2 stimuli, and a relatively lower Bax/Bcl-2 ratio 
indicates that MSCs are more resistant to oxidative stress than cells with a higher 
ratio.[28] As indicated in Figure 6B, the Bax/Bcl-2 ratio increased ca. 5.30-fold in 
MSCs without Wnt3a after treatment with H2O2, suggesting their low resistance to 
oxidative stress. Nevertheless, a significant decrease in the Bax/Bcl-2 ratio was found 
for the two Wnt3a-treated groups compared with the MSC group without Wnt3a 
under oxidative stress conditions, which indicated the protective effect of Wnt3a 
treatment on MSCs. Importantly, compared with the free Wnt3a treatment (ratio of 
1.03), the Wnt3a@TPSi NP labeling further decreased the Bax/Bcl-2 ratio (0.47) to 
















































































Figure 6. Antioxidative stress effect of free Wnt3a and Wnt3a@TPSi NPs in vitro. (A, 
B) Western blot bands of the apoptosis-related proteins (Bax and Bcl-2) and the 
corresponding Bax/Bcl-2 ratios of the H2O2-stimulated MSCs (denoted H2O2), free 
Wnt3a (CWnt3a=150 ng mL
-1)-treated/H2O2-stimulated MSCs (denoted F150+H2O2), 
and Wnt3a@TPSi NP-labeled (CWnt3a=150 ng mL
-1)/H2O2-stimulated MSCs (denoted 
Si150+H2O2). (C) Cell viabilities of different MSC groups after treatment with H2O2 
for 24 h. Control: control group without H2O2 stimuli, H2O2: H2O2 treatment, TPSi: 
empty TPSi NP (CTPSi=6.1 µg mL
-1), F50: free Wnt3a (CWnt3a=50 ng mL
-1), F150: free 
Wnt3a (CWnt3a=150 ng mL
-1), Si50: labeling with Wnt3a@TPSi NPs (CWnt3a=50 ng 
mL-1), Si150: labeling with Wnt3a@TPSi NPs (CWnt3a=150 ng mL
-1). (D) Cell 
viabilities of different MSC groups after treatment with H2O2 for different time 
periods (12 h, 24 h and 48 h). #P>0.05, *P<0.05 and ** P<0.01 by the t-test. 
 
For further evaluation, the cell viability of each of the above groups was assessed 
using the CCK-8 assay. Figure 6C indicates that the cell viability of each 
Wnt3a-treated group treated with a Wnt3a concentration of 150 ng mL-1 was higher 
than of the groups treated with 50 ng mL-1, initially revealing the dose-dependent 




































































resulted in ca. 27.2% and 25.0% higher cell viabilities than those of the free Wnt3a 
groups at concentrations of 50 ng mL-1 and 150 ng mL-1, respectively. As shown in 
Figure 6D, this enhancement effect was more evident when the MSCs were exposed 
to H2O2 for longer periods of time. For example, there was no significant difference in 
cell viability between the free Wnt3a and Wnt3a@TPSi NP groups (Cwnt3a: 150 ng 
mL-1) when the cells underwent H2O2 stimuli for only 12 h; however, the viability in 
the latter group increased as much as 70.3% compared to the viability in the former 
group after 48 h of H2O2 treatment, which may be attributed to the long-term 
maintenance of protein bioactivity in Wnt3a@TPSi NPs. Considering that oxidative 
stress generally exists in an infarcted myocardium for a long period of time,[29] the 
sustained cell protection effect through Wnt3a@TPSi NP labeling in MSCs will 
essentially promote cell survival and differentiation for optimal therapeutic effects. 
2.7. US imaging capability 
We also evaluated the in vitro echogenicity of the TPSi NP-labeled MSCs with a 
clinical scanner at a high frequency, 22 MHz. After coincubation of MSCs with TPSi 
NPs at 40 μg mL-1 for 4 h, labeled MSCs (1×106 cells) were collected by 
centrifugation and resuspended in an agarose phantom with a volume of 0.25 mL. 
Additionally, the imaging signals of unlabeled MSCs with the same amount of cells 
and a blank agarose phantom were also studied for comparison. As shown in Figure 
7A-C, the B-mode image of TPSi NP-labeled MSCs was significantly brighter than 




































































software revealed that compared to unlabeled MSCs, TPSi NP-labeled MSCs 
(approximately 61.45 dB) exhibited an approximately 2.3-fold increase in US signal 
intensity (Figure 7D). This result indicates that the TPSi NPs performed well in US 
contrast imaging of the labeled MSCs. We also studied contrast property of TPSi NPs 
alone in the agarose phantom. Only weak signal (2.73 dB) was observed in the 
phantom (Figure 7D). Therefore, the aggregation of TPSi NPs in the MSCs is the only 
possible reason for the significantly improved contrast.[10] 
Furthermore, to understand how particle concentration affects the US signal, we 
imaged the cell samples at 30 MHz after subcutaneous injection of different numbers 
of TPSi NP-labeled MSCs into nude mice. As shown in Figure 7E, no obvious US 
signal was observed in the control group injected with PBS. However, the US signal 
of TPSi NP-labeled MSCs was immediately observed upon implantation when the 
cell number was above 5×104. Importantly, the average US signal intensity of TPSi 
NP-labeled MSCs is about 1.4 fold higher than that of unlabeled cells when the 
equivalent number (2×105) of MSCs were injected (Figure S13). Furthermore, US 
images of different numbers of implanted TPSi NP-labeled MSCs demonstrated a cell 




















































































Figure 7. (A-C) B-mode US images of agarose phantoms containing (A) MSCs, (B) 
TPSi NP-labeled MSCs, and (C) TPSi NPs. (D) The corresponding average US signal 
intensities of the above groups. (E, F) US images (E) and average US signal 
intensities (F) of the subcutaneous tissues after injection with different numbers of 
labeled MSCs. 
2.8. In vivo US-enhanced imaging after intramyocardial injection 
Stem cell transplantation has shown great clinical potential as a primary or 
secondary therapeutic modality for a variety of diseases, particularly cardiac repair.[30] 
To improve the spatial accuracy of transplantation into myocardial tissue, stem cells 
are generally delivered by a combination of left thoracotomy and sequential 
myocardial injection under direct visualization in many preclinical studies.[31] 
Unfortunately, the actual injection site is still not observed accurately with the current 
optical imaging techniques. Herein, to evaluate the US imaging performance of 




































































labeled MSCs and unlabeled MSCs into the left ventricle wall of healthy nude mice. 
As shown in Figure 8A, B, there was no obvious US imaging signal change after the 
injection of unlabeled MSCs. In contrast, a sudden enhancement in imaging signal 
was clearly observed at the 0:17 time point for the labeled MSC group (Figure 8C, D, 
and Movie S1). Additionally, the enhanced region was located inside and fluctuated 
along with the ventricular wall, indicating precise injection of MSCs. More 
importantly, due to the enhanced effect of TPSi NPs, it was easy to ascertain the cell 
distribution by US imaging in the current stage. The statistical profile (Figure 8E, F) 
shows that the US intensity of the labeled MSCs group increased by 2.2-fold 
compared to that of the unlabeled group. Overall, the above in vitro and in vivo 
studies both indicate that TPSi NP-mediated cellular labeling combined with US 










Figure 8. (A-D) US images of the cardiac structure before (A, C) and after (B, D) 
intramyocardial injection of the unlabeled (A, B) and Wnt3a@TPSi NP-labeled MSCs 




































































after MSC injection for the unlabeled (E) and labeled (F) groups. The average US 
intensity of the representative region indicated by the red circle was determined by the 
software SONOMATH. 
 
To investigate the safety of the local myocardial injection of the Wnt3a@PSi 
NP-labeled MSCs, we further carried out a complete blood panel, blood chemistry 
analysis and hematoxylin and eosin (H&E) staining of the main organs of healthy 
Sprague-Dawley (SD) rats 30 days after implantation of the labeled MSCs (2×105 
cells) in the left ventricle wall. SD rats treated with the same number of unlabeled 
MSCs were evaluated as the control group. The hematological and blood test results 
of both MSC-treated groups exhibited no obvious difference from those of the 
untreated mice (Figure S14A-G). Additionally, the histological examination of the 
heart, liver, spleen, lung and kidney showed no noticeable damage, as observed by 
H&E-stained sections (Figure S15), which means that the metabolites and degradation 
products from TPSi carriers are also nontoxic to the major organs. Overall, these 
results provide comprehensive evidence that the designed labeling nanoagent at the 
given dose can be safety administered in vivo. 
3. Conclusion 
We fabricated Wnt3a protein-loaded TPSi NPs as dual-functional US contrast/cell 
protection agents to label MSCs. This TAT-modified and PSi NP-based labeling agent 
was rapidly internalized by MSCs within 4 h and exhibited negligible effects on the 




































































structure and capacity for intracellular degradability can carry Wnt3a proteins with 
high loading efficiency and release them in a sustained manner for antioxidative 
protection of the labeled MSCs. We also determined the sensitivity of TPSi NP 
labeling in US imaging of MSCs using both agarose phantom samples and in vivo 
mouse models. The results demonstrated that the intracellular particle aggregation of 
TPSi NPs could result in clear US signal amplification, which is anticipated to enable 
a considerable improvement in the precision of stem cell transplantation into the 
myocardium. It is considered that stem cell therapy in combination with a 
multifunctional TPSi NP-based theranostic strategy can be extended to wide 
applications, including myocardial infarction, ischemic stroke treatments and cancer 
therapy, and has great potential for future clinical translation. 
 
4. Experimental Section 
Materials: TAT peptide conjugated with FITC (TAT-FITC) was purchased from 
Chinese Peptide Co., Ltd. N-hydroxysuccinimide (NHS) and 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) were purchased from 
Sigma-Aldrich. BD Matrigel was used as a matrix for cell implantation. Low-glucose 
and high-glucose Dulbecco’s modified Eagle’s medium (LG-DMEM and 
HG-DMEM), fetal bovine serum (FBS), and penicillin + streptomycin (PS) were 
obtained from Gibco Company (USA). BMP-2 and FGF-4 were purchased from 




































































respectively. Anti-cardiac troponin I (cTnI) polyclonal antibody (ab47003) and 
anti-GATA-4 monoclonal antibody (134057) and recombinant mouse Wnt3a protein 
were purchased from Abcam Company (UK). Fluorescent secondary antibody was 
obtained from Life Technology (1713763, USA). 
Physical characterizations: Scanning electron microscopy (SEM) images were 
obtained using a Hitachi S-4800 field-emission SEM. Transmission electron 
microscopy (TEM) images of material samples were acquired using a JEM-2100F 
electron microscope with an accelerating voltage of 200 kV. TEM images of cell 
samples were acquired using a JEM-1400 electron microscope with an accelerating 
voltage of 120 kV. The ultraviolet-visible (UV-Vis) spectra were obtained on a 
Shimadzu UV-3101PC UV-Vis spectrophotometer. Fourier transform infrared (FTIR) 
spectroscopy analyses were conducted with a Nicolet 7000-C spectrometer. The 
element concentration in aqueous solution was measured using inductively coupled 
plasma-atomic emission spectrometry (ICP-AES, Agilent). The porous characteristics 
of the material were evaluated using N2 sorption at -196°C using Tristar 3000 
(Micromeritics Inc.). From the isotherm, the specific surface area was calculated 
using the Brunauer-Emmett-Teller (BET) theory and the total pore volume was 
estimated from the total adsorbed amount at a relative pressure of 0.97. 
Preparation of TPSi NPs: Porous silicon multilayer films were first etched by pulsed 
electrochemical anodization of a p-type (100) silicon wafers with a resistivity in the 




































































ethanol, as described previously.[15a] The multilayer film was lifted off from the 
substrate by increasing the anodization current into the electropolishing region. The 
PSi films were thermally carbonized with acetylene and then amine functionalized as 
described elsewhere.[32] Briefly, thermally carbonized PSi (TCPSi) films were 
immersed into HF to generate hydroxyl groups on the surfaces. The OH-terminated 
films were silanized using 10 vol-% mixture of (3-aminopropyl)triethoxysilane 
(APTES) and anhydrous toluene for 1 h at room temperature. After washing the 
excess silane with toluene and ethanol, the films were dried for 16 h at 105°C. The 
APTES-modified TCPSi were then milled down into nanoparticles in a 5 vol-% 
APTES-toluene solution using high energy ball milling. After removal of the excess 
silane with fresh toluene and ethanol, the size selection of the amine-terminated PSi 
NPs was done with centrifugation. 
TAT-FITC peptide (2 mg) was first dissolved in 2.0 mL of 
2-(N-morpholino)ethanesulfonic acid (MES) buffer solution (pH 5.5). Then, 0.1 
mmoL of EDC and 0.25 mmoL of NHS were sequentially added to the TAT solution 
to activate the carboxyl group of TAT. The mixture was stirred gently at room 
temperature for 1 h in the dark, and amine-modified PSi NPs (5 mg) in 5 mL of 
deionized water were then added. The above mixture was further stirred for 1 h at 
room temperature in the dark. The particle was washed with deionized water and 
collected by centrifugation at 14000 rpm. The content of unbound TAT-FITC in 
washing solution was evaluated by UV-Vis spectroscopy. Finally, the product was 




































































measurements were conducted using a Zetasizer Nano analyzer (Malvern). 
Cell labeling process: Mesenchymal stem cells (MSCs) were cultivated in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% (v/v) FBS, 100 units/mL 
penicillin and 100 mg/mL streptomycin in a humidified incubator at 37°C and 5% 
CO2. To label the MSCs with TPSi NPs, TPSi NPs at different concentrations were 
added to the culture medium. After coincubation for 4 h, the MSCs were collected by 
cell dissociation and centrifugation at 1500 rpm. Then, the TPSi NP-labeled MSCs 
were suspended in a centrifuge tube for further biological characterization. 
Material degradation evaluation: To evaluate the degradation behavior of TPSi NPs, 
the amount of silicate ions leached from TPSi NPs was monitored by incubating the 
NPs in PBS at different pH values (8.4, 7.4 and 5.4) and measuring the Si 
concentration of the supernatant solution after centrifugation of the intact TPSi NPs. 
The pH value of the PBS solution was controlled by adding dilute hydrochloric acid 
or triethanolamine. The tubes containing the TPSi NP suspensions were placed on a 
shaking table at 140 rpm and 37°C. Then, the Si concentration in the supernatant was 
measured by ICP-AES. 
Furthermore, to observe the degradation behavior of TPSi NPs in MSCs, the TPSi 
NP-labeled MSCs were incubated in DMEM for different times (1, 8 and 16 days). 
The cells were detached, collected by centrifugation and fixed with glutaraldehyde 
solution (2.5%). Then, the fixed cell sample was dehydrated with a graded ethanol 




































































Later, the ultrathin sections were cut by a diamond knife and observed by the 
JEM-1400 electron microscope. 
Wnt3a loading and the release curve of Wnt3a@TPSi NPs: Ten micrograms of 
recombinant mouse Wnt3a protein was added to sterile water for reconstitution to a 
concentration of 0.1 mg mL-1. To load Wnt3a in TPSi NPs, 50 μL of the above Wnt3a 
solution was mixed with 200 μg of TPSi NPs in 100 μL of PBS (0.01×) for 1 h in a 
4°C ice bath by magnetic stirring. Then, the Wnt3a@TPSi NPs were collected by 
centrifugation at 10000 rpm for 5 min. To analyze the Wnt3a loading efficiency, the 
supernatant was also collected after centrifugation of the above suspension, and the 
Wnt3a concentration was then measured using the Mouse Wnt3a ELISA Kit (Jianglai 
Biological Company, Shanghai, China).  
To characterize the Wnt3a release behavior of Wnt3a@TPSi NPs, a certain mass of 
Wnt3a@TPSi NPs was suspended in 1 mL of sterile ultrapure water. Then, the plastic 
tube containing the above suspension was placed in a water bath shaker at 37°C with 
moderate shaking at 80 rpm. A total of 100 μL of supernatant was collected at 
different time points (4, 8, 12, 24, 48 and 72 h) and centrifuged at 10000 rpm for 5 
min to remove the precipitate. The Wnt3a content in each supernatant was measured 
using an ELISA kit according to the manufacturer’s instructions. 
Evaluation of the antioxidative stress effect of MSCs labeled with Wnt3a@TPSi 
NPs in vitro: The MSCs were seeded in 96-well plates at a density of 5×103 cells per 




































































and 100 mg mL-1 streptomycin for 12 h. Then, the cell medium was replaced with 
low-glucose cell medium containing 100 units per mL penicillin and 100 units/mL 
streptomycin and hydrogen peroxide at different concentrations (0, 50, 100, 200, and 
400 μM). After further incubation for 24 h, the cell viability was evaluated using the 
CCK-8 assay. Finally, a H2O2 concentration of 100 μM was chosen for further cell 
experiments. 
To evaluate the antioxidative stress ability of MSCs labeled with Wnt3a@TPSi 
NPs, the cells were first incubated with different concentrations of Wnt3a protein in 
both the free Wnt3a form and the Wnt3a@TPSi NPs (the Wnt3a concentrations of 
two groups were 50 and 150 ng mL-1, respectively) for 4 h in DMEM containing 10% 
(v/v) FBS, 100 units mL-1 penicillin and 100 units mL-1 streptomycin. The cell 
medium was replaced with the above H2O2-containing/serum-free medium and 
cultured for another 24 h. After washing with PBS twice, cell viability was evaluated 
using the CCK-8 assay following the above procedure. Furthermore, the cell viability 
of the Wnt3a@TPSi NPs-labeled MSCs (the Wnt3a concentration was 150 ng mL-1) 
after cultured in H2O2-containing/serum-free medium for different times (12, 24 and 
48 h) were also evaluated.  
To determine the protein levels (p-GSK-3β, GSK-3β, β-catenin, Bcl-2 and Bax) in 
free Wnt3a-treated and Wnt3a@TPSi NP-treated MSCs, MSCs (2×105 cells per well 
in 6-well plates) were coincubated with each Wnt3a-containing sample for 4 h in 




































































protein in the MSCs was extracted by lysing the cells in lysis buffer. Furthermore, the 
nuclear protein was extracted by the NE-PER Nuclear and Cytoplasmic Extraction Kit 
(Thermo Fisher Scientific, USA) according to the manufacturer’s instructions. The 
protein concentration was quantified via the BCA test (Thermo Fisher Scientific, 
USA). Later, the same amounts (25 µg) of the proteins were separated by means of a 
10% polyacrylamide gel and transferred to polyvinylidene difluoride (PVDF) 
membranes. The membranes were blocked with 5% skim milk, followed by 
incubation with different primary antibodies, including rabbit anti-mouse β-catenin 
(Proteintech, 1:500, 33 kDa), rabbit anti-mouse p-GSK-3β (Cell Signaling Technology, 
1:1000, 46 kDa, USA), anti-mouse GSK-3β (Cell Signaling Technology, 1:1000, 46 
kDa, USA), rabbit anti-mouse Bax (Cell Signaling Technology, 1:1000, 20 kDa, 
USA), mouse anti-mouse Bcl-2 (Novus, 1:500, 24 kDa, USA), mouse anti-mouse 
β-actin (Sigma, 1:5000, 43 kDa, USA) and rabbit anti-mouse lamin B1 (Proteintech, 
1:500, 66 kDa) overnight at 4°C. Then, the secondary antibody (goat anti-mouse 
immunoglobulin G or goat anti-rabbit immunoglobulin G, Cell Signaling Technology, 
USA) was added, and each membrane was incubated for an additional 2 h. Finally, the 
protein bands were visualized by an enhanced chemiluminescence detection kit (ECL, 
Thermo Fisher Scientific, USA) and exposed under a gel imaging system (Tanon 
2500, Tanon Science & Technology Co., Ltd.). The expression of p-GSK3 and total 
GSK3 levels were detected in two different gels with the same loading quality of 
protein samples. The intensity of each band was measured by ImageJ software. 




































































to evaluate their in vitro US scattering signal. First, the labeled and unlabeled MSCs 
with the same amount of cells (1×106 cells) were suspended in 0.25 mL of saline 
solution. At the same time, 1% agarose solution was obtained by adding agarose 
powder to deionized water, followed by heat treatment in a microwave oven for 2 min. 
Then, 0.25 mL of the cell suspension was mixed quickly with 0.25 mL of the agarose 
solution using a vortex mixer. Immediately, 0.25 mL of the mixed solution was added 
to the well of a 96-well plate. Additionally, the solidified 0.5% fresh agarose solution 
was also studied as a control group. The 96-well plate was placed under degassed 
water and scanned by the clinical US imaging system (GE Healthcare, mechanical 
index (MI): 0.7, transducer frequency: 22 MHz). The US image of each sample was 
recorded, and the US intensity was read by the software SONOMATH (Ambition Co. 
Ltd., Chongqing, China). Three fields of view for each sample were collected to 
obtain the average intensity. 
In vivo US imaging of Wnt3a@TPSi NP-labeled MSCs in a nude mouse model: The 
animal procedure follows the guidelines of the institutional Animal Care and Use 
Committee at Tongji University. Balb/c nude mice (weight of approximately 20 g) 
were purchased from Shanghai SLAC Laboratory Animal Co. Ltd. After coincubation 
of MSCs cells with Wnt3a@TPSi NPs at 40 μg mL-1 for 4 h, the labeled MSCs cells 
were detached from the culture dish and suspended in 1 mL of PBS. The cells were 
counted by a hemocytometer. Different numbers of labeled MSCs were resuspended 
in 200 µL of 1:1 PBS/Matrigel and injected subcutaneously into nude mice. The US 




































































(FUJIFILM Visual Sonics, Inc., USA) at a frequency of 30 MHz. The US intensity of 
the region of interest was read by the software SONOMATH. 
Furthermore, to evaluate the in vivo US imaging performance of the labeled 
MSCs applied via intramyocardial injection, 0.5 mL of Matrigel was mixed gently 
with 0.5 mL of PBS containing 2×106 labeled MSCs at 4°C. Nude mice were 
anesthetized by isoflurane inhalation and fixed onto the operation platform. Then, 50 
μL of the mixed solution was injected into the left ventricle wall of healthy nude mice 
for US imaging at a frequency of 30 MHz. The US images were recorded before and 
after injection of the sample. 
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The table of contents entry 
A biodegradable, cell penetrating peptide-conjugated, porous silicon nanoparticle 
loaded with Wnt3a protein is designed as a labeling nanoagent to increase both the 
antioxidative stress effect and ultrasound contrast of the labeled stem cells. We 
demonstrate the intracellular aggregation of this protein-loaded nanoplatform is a 
simple and robust theranostic strategy for both stem cell protection and ultrasound 
imaging-guided stem cell transplantation. 
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